ELDN
NASDAQ · Biotechnology
Eledon Pharmaceuticals Inc
$3.69
+0.23 (+6.65%)
Open$3.46
Previous Close$3.46
Day High$3.70
Day Low$3.44
52W High$4.60
52W Low$1.35
Volume—
Avg Volume857.6K
Market Cap285.59M
P/E Ratio—
EPS$-0.83
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+227.6% upside
Current
$3.69
$3.69
Target
$12.09
$12.09
$9.42
$12.09 avg
$15.53
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 30.92M | 31.36M | 28.49M |
| Net Income | 5.14M | 5.83M | 4.48M |
| Profit Margin | 16.6% | 18.6% | 15.7% |
| EBITDA | 8.25M | 8.46M | 8.04M |
| Free Cash Flow | 7.08M | 5.83M | 4.28M |
| Rev Growth | +12.9% | -8.9% | -3.6% |
| Debt/Equity | 0.35 | 0.38 | 0.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |